This is a nationwide, prospective and retrospective, prospective, multicenter observational study that will enroll all B-ALL patients treated in Italy with commercially approved anti-CD19 CAR T cell therapy. The planned enrolment period is 24 months, followed by an additional 12-month follow-up period.
Only clinical and laboratory data produced at participating centers, as per normal clinical practice, will be collected.
Age
Any age
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
1. Diagnosis of ALL R/R CD19+
2. Patients are pediatric (all patients up to the age of 18) adult (all comers older than 18)
3. Prescribed treatment with Tisagenlecleucel or Brexucabtagene autoleucel as per approved AIFA criteria, or obecabtagene autoleucel - as well as other products - when available
4. Provided consent (or did not opposed) for collection and use of patient data per local regulations